AAAAAA

   
Results: 1-7 |
Results: 7
ASSOCIATION OF SERUM RITUXIMAB (IDEC-C2B8) CONCENTRATION AND ANTITUMOR RESPONSE IN THE TREATMENT OF RECURRENT LOW-GRADE OR FOLLICULAR NON-HODGKINS-LYMPHOMA
Authors: BERINSTEIN NL GRILLOLOPEZ AJ WHITE CA BENCEBRUCKLER I MALONEY D CZUCZMAN M GREEN D ROSENBERG J MCLAUGHLIN P SHEN D
Citation: Nl. Berinstein et al., ASSOCIATION OF SERUM RITUXIMAB (IDEC-C2B8) CONCENTRATION AND ANTITUMOR RESPONSE IN THE TREATMENT OF RECURRENT LOW-GRADE OR FOLLICULAR NON-HODGKINS-LYMPHOMA, Annals of oncology, 9(9), 1998, pp. 995-1001
REVIEW OF SINGLE-AGENT IDEC-C2B8 SAFETY AND EFFICACY RESULTS IN LOW-GRADE OR FOLLICULAR NON-HODGKINS-LYMPHOMA (NHL)
Authors: WHITE CA GRILLOLOPEZ AJ MALONEY D BODKIN D CZUCZMAN M MCLAUGHLIN P CABANILLAS F SAVEN A SALEH M
Citation: Ca. White et al., REVIEW OF SINGLE-AGENT IDEC-C2B8 SAFETY AND EFFICACY RESULTS IN LOW-GRADE OR FOLLICULAR NON-HODGKINS-LYMPHOMA (NHL), European journal of cancer, 33, 1997, pp. 91-91
PHASE-II CLINICAL-TRIAL OF OKT3 FOR ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (ALLOBMT)
Authors: ALAM A BAER MR BERNSTEIN S BERNSTEIN Z CHRISTIANSEN N CZUCZMAN M SCHRIBER J SLACK J TEZCAN H WETZLER M COOPER M MILK B FORD L HERZIG G MCCARTHY P
Citation: A. Alam et al., PHASE-II CLINICAL-TRIAL OF OKT3 FOR ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (ALLOBMT), Blood, 90(10), 1997, pp. 449-449
THIOTEPA-ASSOCIATED CARDIOMYOPATHY DURING HEMATOPOIETIC STEM-CELL TRANSPLANTATION
Authors: ALIDINA A BAER R BERNSTEIN S BERNSTEIN Z CHRISTIANSEN N CZUCZMAN M SCHRIBER J SLACK J SPANGENTHAL T TEZCAN H WETZLER M MILK B SWINNICH D FORD L HERZIG G MCCARTHY P
Citation: A. Alidina et al., THIOTEPA-ASSOCIATED CARDIOMYOPATHY DURING HEMATOPOIETIC STEM-CELL TRANSPLANTATION, Blood, 90(10), 1997, pp. 984-984
RITUXAN(TM) (RITUXIMAB, IDEC-C2B8) - INTERIM ANALYSIS OF A PHASE-II STUDY OF ONCE WEEKLY TIMES 8 DOSING IN PATIENTS WITH RELAPSED LOW-GRADEOR FOLLICULAR NON-HODGKINS-LYMPHOMA
Authors: PIRO L WHITE CA LOPEZ AJG JANAKIRAMAN N BECK TM SELANDER K DOWDEN S CZUCZMAN M LYNCH JW KOLITZ JE JAIN V
Citation: L. Piro et al., RITUXAN(TM) (RITUXIMAB, IDEC-C2B8) - INTERIM ANALYSIS OF A PHASE-II STUDY OF ONCE WEEKLY TIMES 8 DOSING IN PATIENTS WITH RELAPSED LOW-GRADEOR FOLLICULAR NON-HODGKINS-LYMPHOMA, Blood, 90(10), 1997, pp. 2272-2272
ANTI-CD20 ANTIBODY (MAB), IDEC-C2B8 - CLEARANCE OF BCL-2 T(14-18) POSITIVE CELLS FROM PERIPHERAL-BLOOD (PB) AND BONE-MARROW (BM) IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/
Authors: CABANILLAS F GRILLOLOPEZ AJ MCLAUGHLIN P LINK BK LEVY R CZUCZMAN M HEYMAN MR WILLIAMS M JAIN V BENCEBRUCKLER I HO AD LISTER J ROGER J SHEN D VARNS C
Citation: F. Cabanillas et al., ANTI-CD20 ANTIBODY (MAB), IDEC-C2B8 - CLEARANCE OF BCL-2 T(14-18) POSITIVE CELLS FROM PERIPHERAL-BLOOD (PB) AND BONE-MARROW (BM) IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/, Blood, 88(10), 1996, pp. 351-351
IDEC-C2B8 CHOP CHEMOIMMUNOTHERAPY IN PATIENTS WITH LOW-GRADE LYMPHOMA- CLINICAL AND BCL-2 (PCR) FINAL RESULTS/
Authors: CZUCZMAN M GRILLOLOPEZ AJ WHITE CA SALEH M GORDON L LOBUGLIO AF JONAS C DALLAIRE B VARNS C
Citation: M. Czuczman et al., IDEC-C2B8 CHOP CHEMOIMMUNOTHERAPY IN PATIENTS WITH LOW-GRADE LYMPHOMA- CLINICAL AND BCL-2 (PCR) FINAL RESULTS/, Blood, 88(10), 1996, pp. 1799-1799
Risultati: 1-7 |